MARKET

MYL

Mylan NL
MYL
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
487.85
0.7131
0.6532
8,586,209,642.01
News
Financial
Releases
Corp Actions
Analysis
Profile
What We Know About How Moderna and Pfizer Vaccines Compare
“Efficacy is likely the same,” Raymond James analyst Steven Seedhouse surmises. A surer comparison will become possible when both trials report detailed results in medical journals.
Barrons.com · 11/16/2020 20:19
Benzinga Pro's Top 5 Stocks To Watch For Monday, Nov. 16, 2020: MRNA, WMT, MYL, NVDA, IMMR
Today's 5 Stock Ideas:  Moderna (MRNA) - Vaccine news out of the company is moving the entire stock market Monday morning. Moderna reported its COVID-19 vaccine showed 95% effectiveness. The stock was up
Benzinga · 11/16/2020 13:40
Pfizer's Upjohn spinoff completes merger with Mylan to form Viatris
Pfizer (PFE) completes the deal to spin off its Upjohn business and combine it with Mylan NV (MYL) to form Viatris (VTRS), which will start trading tomorrow under the ticker
Seekingalpha · 11/16/2020 13:00
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15/2020 15:14
Is Pfizer Stock A Buy After Its Coronavirus Vaccine Proved 90% Effective?
Investor's Business Daily · 11/13/2020 20:22
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06/2020 12:47
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended September 30, 2020.
PR Newswire · 11/06/2020 11:59
Why Mylan (MYL) Might Surprise This Earnings Season
Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 11/02/2020 13:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYL. Analyze the recent business situations of Mylan NL through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYL stock price target is 22.53 with a high estimate of 35.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 704
Institutional Holdings: 531.54M
% Owned: 98.15%
Shares Outstanding: 541.55M
TypeInstitutionsShares
Increased
122
15.84M
New
72
905.94K
Decreased
109
14.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.73%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Executive Director/Director
Robert Coury
President/Executive Director
Rajiv Malik
Chief Executive Officer/Executive Director
Heather Bresch
Non-Executive Vice Chairman/Lead Director/Independent Director
Mark Parrish
Non-Executive Independent Director
Robert Cindrich
Non-Executive Independent Director
JoEllen Dillon
Non-Executive Independent Director
Neil Dimick
Non-Executive Independent Director
Melina Higgins
Non-Executive Independent Director
Harry Korman
Non-Executive Independent Director
Richard Mark
Non-Executive Independent Director
Pauline van der Meer Mohr
Non-Executive Independent Director
Randall Vanderveen
Non-Executive Independent Director
Sjoerd Vollebregt
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
06/18/2007
Dividend USD 0.06
06/27/2007
03/15/2007
Dividend USD 0.06
03/28/2007
12/19/2006
Dividend USD 0.06
12/27/2006
09/19/2006
Dividend USD 0.06
09/27/2006
06/16/2006
Dividend USD 0.06
06/28/2006
03/21/2006
Dividend USD 0.06
03/29/2006
12/20/2005
Dividend USD 0.06
12/28/2005
09/20/2005
Dividend USD 0.06
09/28/2005
06/14/2005
Dividend USD 0.06
06/28/2005
03/17/2005
Dividend USD 0.03
03/29/2005
12/20/2004
Dividend USD 0.03
12/29/2004
09/20/2004
Dividend USD 0.03
09/28/2004
06/17/2004
Dividend USD 0.03
06/28/2004
--
Dividend USD 0.03
03/29/2004
--
Dividend USD 0.03
12/29/2003
--
Dividend USD 0.0333
09/26/2003
--
Dividend USD 0.0333
06/26/2003
--
Dividend USD 0.0333
03/27/2003
--
Dividend USD 0.05
12/27/2002
--
Dividend USD 0.04
09/26/2002
--
Dividend USD 0.04
06/26/2002
--
Dividend USD 0.04
03/26/2002
--
Dividend USD 0.04
12/27/2001
--
Dividend USD 0.04
09/26/2001
--
Dividend USD 0.04
06/27/2001
--
Dividend USD 0.04
03/28/2001
--
Dividend USD 0.04
12/27/2000
09/14/2000
Dividend USD 0.04
09/27/2000
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of Mylan NL stock information, including NASDAQ:MYL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYL stock methods without spending real money on the virtual paper trading platform.